Design, anticonvulsive and neurotoxic properties of retrobenzamides - N-(nitrophenyl)benzamides and N-(aminophenyl)benzamides
Bourhim, M;Poupaert, Jacques;Stables, JP.;Vallee, L.;Vamecq, J.
(1999) Arzneimittel-Forschung — Vol. 49, n° 2, p. 81-87 (1999)
Files
No attached file found for this publication.
Details
Authors
Bourhim, M
Author
Poupaert, JacquesUCLouvain
Author
Stables, JP.
Author
Vallee, L.
Author
Vamecq, J.
Author
Abstract
Design, anticonvulsant properties in maximal electroshock-induced seizures [MES] and seizures induced by subcutaneous administration of pentetrazole (scPtz), and neurotoxicity of retrobenzamides (N-(nitrophenyl)benzamides and N-(aminophenyl) benzamides are reported. These data are further compared with those on carbamazepine, phenytoin, ameltolide and other reference compounds. Studies on retrobenzamides in mice dosed intraperitoneally point out a good anticonvulsant potential in the MES test for the amino derivatives (N-(aminophenyl)benzamides) and moderate activity for corresponding "nitro" derivatives. In rats dosed orally, aminoretrobenzamides were, however, less active in the MES test than in mice dosed intraperitoneally. Differences between experimental animal species and administration routes lead to hypothesize rapid metabolization of compounds, reduced intestinal resorption and increased removal from body. The presence of a methyl substitution on the N-phenyl moiety of aminoretrobenzamides attenuated these discrepancies between mice and rats. Present results indicate that pharmacological values - including the dose offering anticonvulsant protection in 50 % of tested animals (ED50) and protective indices - obtained on some retrobenzamides may compete with phenytoin and carbamazepine values. By contrast with phenytoin, some retrobenzamides further exhibit activity in the scPtz test.
Bourhim, M., Poupaert, J., Stables, JP., Vallee, L., & Vamecq, J. (1999). Design, anticonvulsive and neurotoxic properties of retrobenzamides - N-(nitrophenyl)benzamides and N-(aminophenyl)benzamides. Arzneimittel-Forschung, 49(2), 81-87. https://hdl.handle.net/2078.5/44267 (Original work published 1999)